Clinical trials: Oral Cancer Directed Therapy
Oral Cavity Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8
Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial
This phase II trial studies how well personalized neck radiation therapy directed by sentinel lymph node biopsy (SLNB) works in treating patients with oral cavity squamous cell carcinoma (OCSCC).
- Conditions
- Oral Cavity Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8
- Trial name
- NCT07121595
- Testing
- Biospecimen Collection, Carboplatin, Cisplatin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Michigan Rogel Cancer Center
Non-small Cell Lung Cancer
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
The purpose of this study is to compare the anti-tumor efficacy of oral single-agent rociletinib, as measured by investigator assessment of the PFS, with that of single-agent cytotoxic chemotherapy in patients with EGFR-mutated…
- Trial name
- NCT02322281
- Testing
- Rociletinib, Pemetrexed or gemcitabine or paclitaxel or docetaxel
- Where
- 80 sites in United States, Australia and 8 more
- Volunteers
- 149 people
- Sponsor
- Clovis Oncology, Inc.
Oral Cancer Directed Therapy, Breast Cancer
EHR-embedded OCDT in Breast or GI Cancer
This is research study is for participants with advanced breast or gastrointestinal cancer who have been taking oral chemotherapy medication (Oral Cancer Directed Therapy).
- Conditions
- Oral Cancer Directed Therapy, Breast Cancer, Gastrointestinal Cancer, Oral Chemotherapy
- Trial name
- NCT03858712
- Testing
- Active Care Team Alert, Passive Care Team Alert
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer Metastatic
Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide
The aim of the study is to assess the clinical utility of 11C or 18F-Choline Positron Emission Tomography (PET)/Computed Tomography (CT) scan, Whole Body Magnetic Resonance Imaging (MRI) versus conventional bone scan and…
- Trial name
- NCT02815033
- Testing
- Enzalutamide, 11C or 18F-Choline PET/CT, Whole body MRI
- Where
- Netherlands
- Volunteers
- 66 people
- Sponsor
- The European Uro-Oncology Group
Pancreatic Cancer
Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00303927
- Testing
- capecitabine
- Where
- 2 sites in United States, Spain
- Volunteers
- 65 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Melanoma, Breast Carcinoma
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity…
- Conditions
- Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma
- Trial name
- DUET-2 (NCT03517488)
- Testing
- XmAb20717
- Where
- 17 sites in United States
- Volunteers
- 150 people
- Sponsor
- Xencor, Inc.
Non-small Cell Lung Cancer
Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer
The purpose of this study is to evaluate the safety and anti-tumor effect of rociletinib. The trial is open-ended, which means patients will continue to take rociletinib until the study doctor determines it is no longer…
- Trial name
- NSCLC (NCT02147990)
- Testing
- Rociletinib
- Where
- 91 sites in United States, Australia and 10 more
- Volunteers
- 318 people
- Sponsor
- Clovis Oncology, Inc.
Non-small Cell Lung Cancer
Rociletinib (CO-1686) USA Expanded Access Program
To provide access to rociletinib for patients with advanced or metastatic EGFR-mutant NSCLC who have been treated previously with EGFR directed therapy and have evidence of a T790M mutation (T790M+).
- Trial name
- NCT02547675
- Testing
- Rociletinib
- Where
- 11 sites in United States
- Sponsor
- Clovis Oncology, Inc.
Primary Systemic Amyloidosis
Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial
In this study the investigators want to find out more about the addition of the antibiotic, doxycycline, to standard anti-amyloid therapy in people with amyloidosis.
- Trial name
- DUAL (NCT02207556)
- Testing
- Doxycycline
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Medical College of Wisconsin
Locally Advanced or Metastatic Non Small Cell Lung Cancer
Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients
Rociletinib is a novel, potent, small molecule irreversible tyrosine kinase inhibitor (TKI) that selectively targets mutant forms of the epidermal growth factor receptor (EGFR) while sparing wild-type (WT) EGFR.
- Trial name
- NCT01526928
- Testing
- Rociletinib
- Where
- 49 sites in United States, Australia and 2 more
- Volunteers
- 612 people
- Sponsor
- Clovis Oncology, Inc.